Toxicity of MRI and CT contrast agents (Q22306013)

magnetic resonance imaging

Europe PubMed Central

title

Toxicity of MRI and CT contrast agents (English)

0 references

1 reference

0 references

0 references

Kendra M Hasebroock

1

Kendra M

Hasebroock

1 reference

PubMed

PubMed publication ID

19368492

6 April 2023

Natalie J Serkova

series ordinal

2

author given names

Natalie J

author last names

Serkova

1 reference

PubMed

PubMed publication ID

19368492

Expert Opinion on Drug Metabolism & Toxicology

6 April 2023

language of work or name

English

0 references

publication date

April 2009

0 references

published in

0 references

volume

5

0 references

issue

4

0 references

page(s)

403-416

0 references

1 reference

https://api.crossref.org/works/10.1517/17425250902873796

Prophylaxis strategies for contrast-induced nephropathy

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/17425250902873796

Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/17425250902873796

Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/17425250902873796

Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/17425250902873796

Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/17425250902873796

Origins of computed tomography.

20 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Advanced imaging concepts: a pictorial glossary of CT and MRI technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Functional magnetic resonance imaging of the kidney using macromolecular contrast agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Quantitative contrast-enhanced computed tomography: is there a need for system calibration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

A comparison of tumour perfusion assessed by deconvolution-based analysis of dynamic contrast-enhanced CT and MR imaging in patients with squamous cell carcinoma of the upper aerodigestive tract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography of the head and neck: an atlas of normal uptake and variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Magnetic resonance spectroscopic imaging. Evaluating responses to therapy for gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Assessing kidney function--measured and estimated glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Imaging patients with chronic kidney disease: CIN or NSF?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Pathophysiology of contrast-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Contrast-induced nephropathy: the wheel has turned 360 degrees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Nephrogenic systemic fibrosis: early recognition and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Nephrotoxic effects in high-risk patients undergoing angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Comparative tolerability of contrast media used for coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Snapshot magnetic resonance imaging (Nobel lecture).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Quantitative assessment of glomerular filtration rate with MR gadolinium slope clearance measurements: a phase I trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

How accurate is dynamic contrast-enhanced MRI in the assessment of renal glomerular filtration rate? A critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Functional imaging in CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Iodinated contrast media and their adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Frequency, management, and outcome of extravasation of nonionic iodinated contrast medium in 69,657 intravenous injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Incidence and outcomes of contrast-induced AKI following computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Adverse reactions to iodinated contrast media

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Anaphylactoid reactions to radiocontrast media

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Incidence and severity of acute allergic-like reactions to i.v. nonionic iodinated contrast material in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Contrast media: interactions with other drugs and clinical tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Sodium bicarbonate versus normal saline for protection against contrast nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Systematic review of the impact of N-acetylcysteine on contrast nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Extracellular gadolinium-based contrast media: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

New synthesis of a high molecular weight ligand derived from dota; thermodynamic stability of the MRI contrast agent formed with gadolinium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Safety of magnetic resonance contrast media

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Treatment of nephrogenic systemic fibrosis: limited options but hope for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Molecular framework for response to imatinib mesylate in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

Is NSF only the tip of the "gadolinium toxicity" iceberg?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

7 January 2021

Scintigraphy with positron-emitting compounds.--I. Carbon-11 labeled thymidine and thymidylate

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

7 January 2021

High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

7 January 2021

Gadolinium use in patients with kidney disease: a cause for concern

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

7 January 2021

Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

7 January 2021

Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

7 January 2021

Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

7 January 2021

Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

7 January 2021

Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

7 January 2021

Trends in adverse events after IV administration of contrast media

1 reference

https://api.crossref.org/works/10.1517%2F17425250902873796

7 January 2021